News From EULAR 2012: New Drug Targets Emerge for RA
As basic research on new targets for rheumatoid arthritis (RA) treatment continues, novel therapies move through phase II trials.
New Oral JAK Inhibitors Wait in the Wings
The Janus kinase ( JAK) molecule is an immunomodulating signal transduction agent, which has emerged as a new target for rheumatoid arthritis (RA) research.
2012 Treatment Guidelines for Rheumatoid Arthritis: An Update from the American College of Rheumatology
During the past decade, changes in the treatment of rheumatoid arthritis (RA) have been accumulating faster than treatment experience can be evaluated.
Researching the Cause of Rheumatoid Arthritis
Despite decades of investigation, the causes of rheumatoid arthritis (RA) have remained elusive.
